ArticleeLife2022
Hematopoietic stem and progenitor cells improve survival from sepsis by boosting immunomodulatory cells.
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- IL-27 limits HSPC differentiation during infection and protects from stem cell exhaustion.eLife · 2025Article
- Development of Thymic Organoids Heterotopically to Educate and Induce T Lymphocytes.Immunity, inflammation and disease · 2025Article
- Lymphadenopathy and synovial hyperplasia are associated with sepsis risk in an experimental model of rheumatoid arthritis.Frontiers in immunology · 2025Article
- Human liver stem cells and derived extracellular vesicles protect from sepsis-induced acute lung injury and restore bone marrow myelopoiesis in a murine model of sepsis.Intensive care medicine experimental · 2024Article
- Survivors of polymicrobial sepsis are refractory to G-CSF-induced emergency myelopoiesis and hematopoietic stem and progenitor cell mobilization.Stem cell reports · 2024Article
- Schistosome Infection Impacts Hematopoiesis.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Destabilisation of T cell-dependent humoral immunity in sepsis.Clinical science (London, England : 1979) · 2024Review
- The potential immunological mechanisms of sepsis.Frontiers in immunology · 2024Review
- Harnessing bioengineered myeloid progenitors for precision immunotherapies.NPJ Regenerative medicine · 2023Review
- Hematopoietic stem and progenitor cells confer cross-protective trained immunity in mouse models.iScience · 2023Article
- Dismantling the tumoral cloak of self-protection.PLoS biology · 2023Article
- Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?Frontiers in immunology · 2023Review
- Assessment of safety and immunogenicity of MHC homozygous iPSC-derived CD34+ hematopoietic progenitors in an NHP model.Blood advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
New therapeutic strategies to reduce sepsis-related mortality are urgently needed, as sepsis accounts for one in five deaths worldwide. Since hematopoietic stem and progenitor cells (HSPCs) are responsible for producing blood and immune cells, including in response to immunological stress, we explored their potential for treating sepsis. In a mouse model of Group A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.